🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Study of Natural Course Progression of Diabetic Retinopathy

Recruitingn/aAges 18 Years - 75 YearsAllJie Li
NCT06269419 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this observational study is to observe the formation and development of the non-perfusion area of diabetic retinopathy in the posterior area of the retina in type 2 diabetes patients aged 18-75 years old, who can cooperate with all examinations and sign informed consent, clinical myopathy examination and Optos 7 field of vision with mild than severe NPDR, and no other exclusion indicators.The main questions it aims to answer are whether posterior retinal non-perfusion area occurs earlier than peripheral non-perfusion area and whether the rate of non-perfusion area expansion is a risk factor for the progression of diabetic retinopathy. Participants will have protocol-specific follow-up examinations at 1, 2, 3, 4, and 5 years (± 3 months). Additional visits are made as required by the study and the patient's condition. The contents of follow-up examinations are: History of o

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion criteria: * Patients with type 2 diabetes aged 18-75 years * Can cooperate with the inspection and sign the informed consent * There are no other eye diseases that cause retinal neovascularization * There is no known substantial media haze that would hinder fundus image acquisition * No history of fundus laser treatment or no possibility of laser treatment expected within six months * No previous history of intravitreal drug injection, and no intravitreal drug injection is expected in the next 6 months * Macular edema without diabetes (Zeiss OCT women \< 290µm, male \< 305µm; OCT female in Heidelberg is \< 305µm, and for males \< 320µm) * In the field of visual field of clinical mydriasis and Optos photo 7 field of view, DR Lesions were less severe than NPDR * No history of eye surgery Exclusion criteria: * Patients with kidney failure. * History of systemic anti-VEGF therapy within the last month. * Follow-up is expected to be difficult or patients from other provinces have traction retinal detachment; * The patient has a history of allergy
💊

What it tests

  • Not listed
📍

Where

1 site
Sichuan Academy of Medical Science Sichuan Provincial Hosptial
Chengdu, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy